Diabetic Macular Edema

Data show that the combination of navigated laser and anti-vascular endothelial growth factor (VEGF) compares favorably with anti-VEGF monotherapy.

One center’s initial post-marketing experience with the fluocinolone acetonide intravitreal implant 0.19 mg demonstrates favorable outcomes and good patient acceptance.

A novel ophthalmic micropump system, implanted through minimally invasive surgery, is able to deliver the appropriate amount of drug needed at determined intervals, according to Mark S. Humayun, MD, PhD.

ALG-1001 is the first of a new class of drugs, integrin peptide therapy, now going through clinical trials for patients with age-related macular degeneration, diabetic macular edema, and vitreomacular traction.

Medical advances run gamut from AMD to symptomatic vitreomacular adhesion